INGELHEIM, Germany - Monday, June 27th 2016 [ME NewsWire] For the first time the analysis shows that disease progression is similar in IPF patients identified using a broader diagnostic definition compared with the current diagnostic guidelines OFEV® is effective in slowing disease progression in both diagnostic subgroups which confirms the efficacy of OFEV® across a broad range of IPF patients Analysis has implications on criteria used to diagnose IPF in clinical practice as well as in future clinical trials design (BUSINESS WIRE)-- New analysis of the INPULSIS® trials show for the first time that disease progression is similar in idiopathic pulmonary fibrosis (IPF) patients identified using a broader diagnostic definition compared with the current diagnostic guidelines. The post-hoc analysis of these 1,061 patients has now been published in the American Journal of Respiratory and Critical Care Medicine. IPF is a devastating and fatal condition. Physicians use an imaging techniq ... Read more »

- Both Companies Expected to Become Global Leaders in Two Different Sectors of the Pharmaceutical Market1 - PARIS & INGELHEIM, Germany - Monday, June 27th 2016 [ME NewsWire] (BUSINESS WIRE)-- Sanofi and Boehringer Ingelheim announced today the signing of contracts to secure the strategic transaction initiated in December 2015 which consists of an exchange of Sanofi’s animal health business (“Merial”) and Boehringer Ingelheim’s consumer healthcare (CHC) business. This step marks a major milestone before closing of the transaction which is expected by year-end 2016 and remains subject to approval by all regulatory authorities in different territories. The integration of Boehringer Ingelheim’s Consumer Healthcare (CHC) business into Sanofi and Merial into Boehringer Ingelheim would start after closing. Upon closing this transaction will be a significant business swap in the pharmaceutical sector and an important event in the history of both companies. Prof Dr Andreas Barner, Chairman ... Read more »

- Both Companies Expected to Become Global Leaders in Two Different Sectors of the Pharmaceutical Market1 - PARIS & INGELHEIM, Germany - Monday, June 27th 2016 [ME NewsWire] (BUSINESS WIRE)-- Sanofi and Boehringer Ingelheim announced today the signing of contracts to secure the strategic transaction initiated in December 2015 which consists of an exchange of Sanofi’s animal health business (“Merial”) and Boehringer Ingelheim’s consumer healthcare (CHC) business. This step marks a major milestone before closing of the transaction which is expected by year-end 2016 and remains subject to approval by all regulatory authorities in different territories. The integration of Boehringer Ingelheim’s Consumer Healthcare (CHC) business into Sanofi and Merial into Boehringer Ingelheim would start after closing. Upon closing this transaction will be a significant business swap in the pharmaceutical sector and an important event in the history of both companies. Prof Dr Andreas Barner, Chairman ... Read more »

AVEZZANO, Italy & SHANGHAI - Saturday, June 25th 2016 [ME NewsWire] (BUSINESS WIRE)-- Semiconductor Manufacturing International Corporation (“SMIC”; NYSE: SMI; SEHK: 981), one of the leading semiconductor foundries in the world and the largest and most advanced foundry in mainland China, jointly announces with LFoundry Europe GmbH (“LFE”) and Marsica Innovation S.p.A. (“MI”), the signing of an agreement on June 24, 2016 to purchase a 70% stake of LFoundry for a consideration of 49 million EUR. LFoundry is an integrated circuit wafer foundry headquartered in Italy, which is owned by LFE and MI. At the closing, SMIC, LFE and MI will own 70%, 15% and 15% of the corporate capital of the target respectively. This acquisition benefits both SMIC and LFoundry, through increased combined scale, strengthened overall technology portfolios, and expanded market opportunities for both parties to gain footing in new market sectors. This also represents the Mainland China IC foundry industry’s first ... Read more »